Investors looking to supercharge their portfolios often benefit from a broader stock search. One simple way to do that is to look at year-ahead earnings forecasts. Our picks for the seven best stocks for magnificent earnings growth include Privia Health and Ceva — stocks far less obvious than Meta, Amazon, Netflix or other megacaps that dominate the market.
Seven Best Stocks For Magnificent Earnings Growth
GE Vernova: The General Electric energy spinoff is seeing end markets recover. It has guided growth across business segments. Vernova is poised to benefit from the growth of artificial intelligence (AI) data centers, which consume vast amounts of energy. Wall Street expects Vernova earnings to surge 1,086% in the year ahead and to jump 64% next year, FactSet shows. GE Vernova stock flourishes a Composite Rating of 93 and RS Rating of 97. It is up almost 11% year to date. The fourth-quarter earnings report showed an improving wind business.
TG Therapeutics: A commercial-stage biopharmaceutical company, TG sells a multiple sclerosis treatment called Briumvi, which has driven growth. On a per-share basis, analysts forecast TG will see a 566% surge in earnings in the year ahead as sales jump 66%. It earns a spot on the best stocks for magnificent growth list after a recent turn to profits. TG Therapeutics stock shows a Composite Rating of 77 and RS Rating of 94. It has gained around 2% so far in 2025.
EQT, Privia Health On Best Stocks List
Privia Health: The company provides technology for doctors and health systems. Analysts forecast earnings will soar 97% in the year ahead on 11% revenue growth. Privia Health's earnings are tracking to a decline for 2024. Privia Health stock holds an IBD Composite Rating of 96 and RS Rating of 90, both out of a best-possible 99. A new entry to the best stocks list, the medical software maker has jumped around 29% so far this year. Earnings are due on Feb. 27.
EQT: A vertically integrated natural gas company, EQT focuses on the Appalachian basin. EQT has divested non-operating and midstream assets to focus on the core business plan, analysts say. Further, EQT may benefit from the new Donald Trump administration's more favorable stance toward fossil fuels. The company delivered a Q4 earnings beat-and-raise report on Feb. 18. Analysts now expect EQT earnings per share to leap 85% in the year ahead, after a two-year slide, as sales recover 27%. EQT stock holds a Composite Rating of 85 and RS Rating of 91. It has leaped 13% higher year to date.
Kyndryl, Gilead, Ceva Among The Best Stocks
Gilead Sciences: The biopharmaceutical company's biggest moneymaker is an HIV treatment called Biktarvy. Gilead also makes Covid treatment Veklury. On Feb. 12, the company smashed fourth-quarter forecasts and issued an upbeat profit outlook for 2025. Analysts now forecast Gilead earnings per share will soar 69% in the year ahead, reversing three years of declines. Sales growth is expected to tick higher in 2026 after a drop in 2025. Gilead stock shows a Composite Rating of 88 and RS Rating of 92. It is up around 18% so far this year.
Kyndryl: The IT infrastructure services company was spun out of IBM in 2021. Kyndryl says it is deliberately "engineering a decline in revenue to get rid of low- or no-margin businesses" and achieve profitable growth. Signings are growing and margins expanding due to demand from cloud hyperscalers, the company says. After Kyndryl raised outlook on Feb. 3, analysts expect a 68% earnings jump in the year ahead as sales nudge up after three down years. Kyndryl stock shows a Composite Rating of 92 and RS Rating of 95. It has jumped 13% so far in 2025.
Ceva: The fabless chipmaker more than tripled earnings in 2024 as sales recovered 10%, helping it enter the best stocks list. Four analysts hiked price targets on Ceva stock after the company's Q4 report on Feb. 13, and no one cut, FactSet shows. They forecast Ceva earnings will grow 46% in 2025 and 73% in 2026. Sales are seen growing 8% and 12% over those periods. Ceva stock shows a Composite Rating of 93 and RS Rating of 94. It has climbed 15% so far in 2025. Volume is light.
Universe of S&P 500, S&P 400 and S&P 600 Stocks
A little background on IBD's process to select the best stocks for magnificent earnings growth:
We began our screening process with the S&P Composite 1500 index, which aggregates the S&P 500, S&P MidCap 400 and S&P SmallCap 600 companies. We chose this index, in part, because it avoids less-liquid, lower-priced and lower-quality names, while efficiently measuring the total U.S. stock market.
Then we limited the stocks on our best stock list to those showing FactSet consensus ratings of overweight or buy, which means analysts expect them to outperform industry peers. Next we further winnowed down the list, setting up a double hurdle: The stocks had to enjoy some of the strongest FactSet earnings growth estimates for the following fiscal year, while also earning solid IBD ratings, in terms of their Composite Rating and RS Rating.
The resulting seven best stocks for outsize earnings growth are a quite different set from the Magnificent Seven stocks. At the same time, these stocks are worth watching as much as any of the Mag Seven stocks given their outperformance potential.
To find other ideas for the best stocks to buy or watch, check out IBD Stock Lists and other IBD content.
